This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
I read post #59 twice before replying, because I had assumed the opposite.
Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.
Post #59 answers the question as asked. The question underneath it is different.
Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.
Someone should write this up properly, and it should probably not be me.
No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.
Not a conclusion. A place to stand while looking for one.
Nothing to add on the substance. Thank you for taking the question at face value.
Post #63 is right about the mechanism and I think understates the practical bit.
Checked the Retatrutide dose escalation claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
The honest answer on Retatrutide dose escalation is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
The hepatic-steatosis rationale follows directly from glucagon receptor agonism promoting fat oxidation in the liver. Mechanistic plausibility in this field has a poor record of predicting clinical outcomes, which is why the trials matter more than the mechanism.
That is the shape of it. The detail is where I would expect to be corrected.
Counterpoint on Retatrutide dose escalation, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Confirming post #70 from a second method, which matters more than confirming it from a second person.
Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.
This is the sort of thing that ought to be settled and apparently is not.
I had written a reply contradicting post #68 and deleted it. Here is what survived.
On dose escalation: the published protocols escalated in defined steps over defined intervals, and those intervals were chosen to manage tolerability. Compressing them is not a small change to the protocol; it is a different protocol.
Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.
Two sources, same conclusion, and I could not rule out that one copied the other.
Adding thanks rather than a view. I do not have a view worth the space.
Coming back to post #72, because the follow-up matters more than the original answer.
Duration is the other limitation. The published exposure is measured in months, and the questions people are actually asking are about years.
I would hold that lightly until someone with a larger sample weighs in.
Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.
Reading this Retatrutide dose escalation thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
Dose escalation in the published trials: the protocols started at lower doses and escalated by defined steps. The step sizes are documented and they may or may not match what someone self-prescribing would choose.
I would not lead a decision with this, but I would not ignore it either.
Post #78 put the caveat in the right place and I want to underline it.
Whether triple agonism is additive or synergistic is an open question and the published work does not answer it. A phase 2 trial without a dual-agonist comparator arm cannot distinguish the two.
I have kept the units in throughout, for the obvious reason.
Where I would push back on the Retatrutide dose escalation consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Where I part company with post #81, and it is a narrow parting.
How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does not establish safety, durability, or whether real humans differ from the selected population.
Worth one more sentence than it usually gets.
What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.
Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.
An update on my earlier Retatrutide dose escalation post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Confirming post #89 from a second method, which matters more than confirming it from a second person.
A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.
A modest claim, modestly supported.